"In vitro" behaviour of aptamer-functionalized polymeric nanocapsules loaded with 5-fluorouracil for targeted therapy

Mater Sci Eng C Mater Biol Appl. 2019 Oct:103:109828. doi: 10.1016/j.msec.2019.109828. Epub 2019 May 30.

Abstract

New type of nanocapsules based on carboxymethyl chitosan functionalized with AS1411 aptamer and poly(N-vinylpyrrolidone-alt-itaconic anhydride) loaded with 5-Fluorouracil (5-FU) were developed, with the potential to improve the treatment of cancer. Functionalization of nanocapsules with AS1411 aptamer will enhance their recognition by tumor cells, due to the interaction with nucleolin, and subsequent endocytosis. Nanocapsules were prepared by interfacial condensation method in the absence of any toxic crosslinking agents. The condensation reaction took place at the interface between the organic and aqueous phases by opening the anhydride cycles from the copolymer, under the action of the NH2 groups from mixture of chitosan/aptamer-functionalized carboxymethyl chitosan. The nanocapsules diameter varied between 100 and 267 nm as a function of the molar ratio of the polymers. SEM images have revealed that nanocapsules were spherical and presented relatively low dimensional polydispersity. Nanocapsules swelling degree was found between 1000 and 1680% in PBS solution (pH = 7.4) and they allowed the encapsulation of an important amount of 5-Fluorouracil (5-FU). The release efficiency of 5-FU was studied, the processes being controlled by the drug diffusion through the polymeric membrane, as confirmed by the theoretical analysis of the drug release. The cytotoxicity and haemolysis tests performed on the nanocapsules proved their lack of toxicity and their excellent hemocompatibility. The obtained results were encouraging, showing that these original 5-FU-loaded nanocapsules were able to induce a more pronounced cytotoxic effect on neoplastic MCF-7 cells, the occurrence of dead cells being more rapidly than in the case of free 5-FU.

Keywords: 5-fluorouracil; Aptamer-functionalized nanocapsules; Controlled drug release; Cytotoxicity; Hemocompatibility; Human breast carcinoma.

MeSH terms

  • Aptamers, Nucleotide* / chemistry
  • Aptamers, Nucleotide* / pharmacokinetics
  • Aptamers, Nucleotide* / pharmacology
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Delayed-Action Preparations / chemistry
  • Delayed-Action Preparations / pharmacokinetics
  • Delayed-Action Preparations / pharmacology
  • Female
  • Fluorouracil* / chemistry
  • Fluorouracil* / pharmacokinetics
  • Fluorouracil* / pharmacology
  • Humans
  • MCF-7 Cells
  • Nanocapsules* / chemistry
  • Nanocapsules* / therapeutic use
  • Oligodeoxyribonucleotides* / chemistry
  • Oligodeoxyribonucleotides* / pharmacokinetics
  • Oligodeoxyribonucleotides* / pharmacology
  • Particle Size

Substances

  • AGRO 100
  • Aptamers, Nucleotide
  • Delayed-Action Preparations
  • Nanocapsules
  • Oligodeoxyribonucleotides
  • Fluorouracil